|Table of Contents|

Expression of ID3/ID4 gene in bone marrow of patients with acute myeloid leukemia and its clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 21
Page:
4148-4153
Research Field:
Publishing date:

Info

Title:
Expression of ID3/ID4 gene in bone marrow of patients with acute myeloid leukemia and its clinical significance
Author(s):
WANG Yun1; ZHANG Tingjuan2; ZHAO Qi1; LIN Jiang3; QIAN Jun1; ZHOU Jingdong1
1.Department of Hematology;2.Department of Oncology;3.Laboratory Center,the Affiliated People's Hospital of Jiangsu University,Jiangsu Zhenjiang 212002,China.
Keywords:
acute myeloid leukemia; ID3; ID4; clinical implication
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2024.21.024
Abstract:
Objective:To explore the expression and clinical implication of inhibitor of differentiation 3 and inhibitor of differentiation 4(ID3/ID4) genes in patients with acute myeloid leukemia(AML).Methods:Real-time quantitative PCR was applied to detect the transcript level of ID3/ID4 genes in bone marrow mononuclear cells of 32 non-hematological diseases(control group) and 133 newly diagnosed AML.Clinical implication of ID3/ID4 expression was further analyzed in groups.Results:The transcript level of ID3/ID4 was significantly decreased in AML patients compared with the control group(P=0.001 and 0.002,respectively),and ID3 expression was positively correlated with ID4 expression in AML(r=0.282,P=0.001).Receiver operating characteristic curve demonstrated that ID3/ID4 transcript level may be acted as potential biomarker helpful for the diagnosis of AML(AUC=0.682,P=0.001 and AUC=0.673,P=0.002,respectively).Clinically,patients with low expression of ID3 had a slightly lower age and frequency of NRAS mutation than those with high expression of ID3(P=0.054 and 0.053,respectively).ID4 low-expressed patients tended to have a higher white blood cells and frequency of CEBPA mutation compared with ID4 high-expressed patients(P=0.088 and 0.099,respectively).In addition,patients with low ID4 expression showed a slightly lower complete remission rate than those with high ID4 expression in both total AML(P=0.080) and non-M3 AML(P=0.065) after induction therapy.Survival analysis revealed that patients with low ID3 expression had a similar overall survival compared with patients with high ID3 expression among total AML and other subtypes （non-M3 and cytogenetically normal AML）(P＞0.05).However,ID4 low-expressed patients tended to have a lower overall survival than ID4 high-expressed patients(P=0.058),and with statistical significance in non-M3 AML and cytogenetically normal AML(P=0.014 and 0.002,respectively).Conclusion:Reduced ID3/ID4 expression may be common events in AML,and ID4 expression may provide crucial prognostic information.

References:

［1］DINARDO CD，ERBA HP，FREEMAN SD，et al.Acute myeloid leukaemia［J］.Lancet，2023，401(10393):2073-2086.
［2］王万玥，李玉娇，李永丽，等.中国成人急性髓系白血病遗传分子学特征及预后分析［J］.现代肿瘤医学，2024，32（4）:703-708. WANG WY,LI YJ,LI YL,et al.Molecular genetics characterization and prognostic analysis of adult acute myeloid leukemia in China［J］.Modern Oncology，2024，32（4）:703-708.
［3］ARBER DA，ORAZI A，HASSERJIAN RP，et al.International consensus classification of myeloid neoplasms and acute leukemias:Integrating morphologic,clinical,and genomic data［J］.Blood，2022，140(11):1200-1228.
［4］KHOURY JD，SOLARY E，ABLA O，et al.The 5th edition of the World Health Organization Classification of haematolymphoid tumours:Myeloid and histiocytic/dendritic neoplasms［J］.Leukemia，2022，36(7):1703-1719.
［5］METZELER KH，DUFOUR A，BENTHAUS T，et al.ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia:A comprehensive analysis of ERG,MN1,and BAALC transcript levels using oligonucleotide microarrays［J］.J Clin Oncol，2009，27(30):5031-5038.
［6］倪增峰，刘卉，石利利，等.急性髓系白血病中SMC3基因的表达及意义［J］.现代肿瘤医学，2022，30(11):2042-2045. NI ZF,LIU H,SHI LL,et al.Expression and significance of SMC3 gene in acute myeloid leukemia［J］.Modern Oncology,2022,30(11):2042-2045.
［7］PERK J，IAVARONE A，BENEZRA R.Id family of helix-loop-helix proteins in cancer［J］.Nat Rev Cancer，2005，5(8):603-614.
［8］LASORELLA A，BENEZRA R，IAVARONE A.The ID proteins:Master regulators of cancer stem cells and tumour aggressiveness［J］.Nat Rev Cancer，2014，14(2):77-91.
［9］ZHOU JD，YANG L，ZHU XW，et al.Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia［J］.Int J Clin Exp Pathol，2015，8(5):5336-5344.
［10］ZHOU JD，MA JC，ZHANG TJ，et al.High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia［J］.Oncotarget，2017，8(54):91979-91989.
［11］ARBER DA，ORAZI A，HASSERJIAN R，et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia［J］.Blood，2016，127(20):2391-2405.
［12］LI Y，LIN J，YANG J，et al.Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia［J］.Leuk Res，2013，37(12):1642-1647.
［13］ZHANG TJ，XU ZJ，WEN XM，et al.SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm［J］.Leukemia，2022，36(10):2488-2498.
［14］TANG R，HIRSCH P，FAVA F，et al.High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia［J］.Blood，2009，114(14):2993-3000.
［15］WANG H，WANG XQ，XU XP，et al.ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome［J］.Leuk Res，2010，34(5):598-604.
［16］ZHOU JD，ZHANG TJ，LI XX，et al.Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies［J］.J Cell Mol Med，2017，21(8):1468-1481.
［17］SHARMA P，PATEL D，CHAUDHARY J.Id1 and Id3 expression is associated with increasing grade of prostate cancer:Id3 preferentially regulates CDKN1B［J］.Cancer Med，2012，1(2):187-197.
［18］SHUNO Y，TSUNO NH，OKAJI Y，et al.Id1/Id3 knockdown inhibits metastatic potential of pancreatic cancer［J］.J Surg Res，2010，161(1):76-82.
［19］CHEN D，FOROOTAN SS，GOSNEY JR，et al.Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer［J］.Genes Cancer，2014，5(5-6):212-225.
［20］KAMALIAN L，FOROOTAN SS，BAO ZZ，et al.Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression［J］.Int J Oncol，2010，37(3):595-603.
［21］CHEN FF，LIU Y，WANG F，et al.Effects of upregulation of Id3 in human lung adenocarcinoma cells on proliferation,apoptosis,mobility and tumorigenicity［J］.Cancer Gene Ther，2015，22(9):431-437.
［22］LI XJ，ZHU CD，YU W，et al.Overexpression of Id3 induces apoptosis of A549 human lung adenocarcinoma cells［J］.Cell Prolif，2012，45(1):1-8.
［23］CHEN YS，AUBEE J，DIVITO KA，et al.Id3 induces an Elk-1-caspase-8-dependent apoptotic pathway in squamous carcinoma cells［J］.Cancer Med，2015，4(6):914-924.
［24］DENG Z，LOHYER PL，LAZAROV T，et al.The nuclear factor ID3 endows macrophages with a potent anti-tumour activity［J］.Nature，2024，626(8000):864-873.
［25］GOUBET AG，PITTET MJ.Unveiling the antitumor function of ID3 in liver macrophages［J］.Nat Immunol，2024，25(3):394-395.
［26］CASTAЙON E，BOSCH-BARRERA J，LOPEZ I，et al.Id1 and Id3 co-expression correlates with clinical outcome in stage Ⅲ-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy［J］.J Transl Med，2013，11:13.
［27］ANTONNGELO L，TUMA T，FABRO A，et al.Id-1,Id-2,and Id-3 co-expression correlates with prognosis in stage I and Ⅱ lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy［J］.Exp Biol Med，2016，241(11):1159-1168.
［28］NAGASAKA M，MIYAJIMA C，INOUE Y，et al.ID3 is a novel target gene of p53 and modulates lung cancer cell metastasis［J］.Biochem Biophys Res Commun，2024，708:149789.
［29］YANG HY，LIU HL，LIU GY，et al.Expression and prognostic values of Id-1 and Id-3 in gastric adenocarcinoma［J］.J Surg Res，2011，167(2):258-266.
［30］HUANG L，CAI J，GUO H，et al.ID3 promotes stem cell features and predicts chemotherapeutic response of intrahepatic cholangiocarcinoma［J］.Hepatology，2019，69(5):1995-2012.
［31］HARDER J，MULLER MJ，FUCHS M，et al.Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer［J］.World J Gastroenterol，2013，19(48):9334-9342.

Memo

Memo:
National Natural Science Foundation of China(No.82300164,82270179);国家自然科学基金（编号：82300164,82270179）；江苏省自然科学基金（编号：BK20221287,BK20230296）；江苏省卫健委科研项目（编号：M2022123）；江苏省镇江市社会发展项目（编号：SH2022027，SH2023009）；江苏大学第二十二批学生科研课题立项（编号：Y22A086）
Last Update: 2024-09-30